What is the CEO’s TVTX share ownership after these trades?

Following the reported transactions, the officer directly beneficially owned 419,173 shares of common stock.

TVTX CEO trades: 120,000 shares sold after option exercises

Q: What insider transactions did TVTX’s CEO report?

The CEO exercised options at $15.46 and sold the resulting shares on 10/28/2025 and 10/29/2025 at weighted average prices of $30.379 and $30.1192 , respectively.

Q: How many TVTX shares were sold and at what prices?

A total of 120,000 shares were sold: 92,872 at a weighted average $30.379 (range $30.00–$30.97 ) and 27,128 at $30.1192 (range $30.00–$30.48 ).

Q: Were the TVTX trades under a Rule 10b5-1 plan?

Yes. The sales were made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements.

Q: Were the exercised stock options vested?

Yes. The filing states the stock option is fully vested and exercisable .

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Travere Therapeutics (TVTX) reported insider transactions by its Chief Executive Officer and director under a Rule 10b5-1(c) trading plan adopted on June 16, 2025. On 10/28/2025, the officer exercised 92,872 options at $15.46 and sold 92,872 shares at a weighted average price of $30.379 (range $30.00–$30.97). On 10/29/2025, the officer exercised 27,128 options at $15.46 and sold 27,128 shares at a weighted average price of $30.1192 (range $30.00–$30.48).

Following the reported transactions, the officer beneficially owned 419,173 shares of common stock directly. Derivative securities beneficially owned following the transactions totaled 180,000 options with a $15.46 exercise price expiring on 01/31/2030. The option referenced is fully vested and exercisable.

Insider Trade Summary

Exercise and Sale: 120,000 shares ($1.78M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 120,000 shs ($3.64M)

Approx. gross sale proceeds $3.64M

Approx. exercise cost $1.86M

Approx. pre-tax spread $1.78M

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	27,128	$0.00	$0.00
Exercise	Common Stock	27,128	$15.46	$419K
Sale	Common Stock	27,128	$30.1192	$817K
Exercise	Employee stock option (right to buy)	92,872	$0.00	$0.00
Exercise	Common Stock	92,872	$15.46	$1.44M
Sale	Common Stock	92,872	$30.379	$2.82M

Holdings After Transaction: Employee stock option (right to buy) — 180,000 shares (Direct); Common Stock — 419,173 shares (Direct)

Footnotes (4)

F1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2. The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3. The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4. The stock option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/30/2025 - 04:45 PM

FAQ

What insider transactions did TVTX’s CEO report?

The CEO exercised options at $15.46 and sold the resulting shares on 10/28/2025 and 10/29/2025 at weighted average prices of $30.379 and $30.1192, respectively.

How many TVTX shares were sold and at what prices?

A total of 120,000 shares were sold: 92,872 at a weighted average $30.379 (range $30.00–$30.97) and 27,128 at $30.1192 (range $30.00–$30.48).

Were the TVTX trades under a Rule 10b5-1 plan?

Yes. The sales were made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements.

What derivative securities remain after the transactions?

Derivative securities beneficially owned following the transactions totaled 180,000 options with a $15.46 exercise price, expiring on 01/31/2030.

Were the exercised stock options vested?

Yes. The filing states the stock option is fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/28/2025		M		92,872	A	$15.46	512,045	D
Common Stock	10/28/2025		S⁽¹⁾		92,872	D	$30.379⁽²⁾	419,173	D
Common Stock	10/29/2025		M		27,128	A	$15.46	446,301	D
Common Stock	10/29/2025		S⁽¹⁾		27,128	D	$30.1192⁽³⁾	419,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee stock option (right to buy)	$15.46	10/28/2025		M			92,872	⁽⁴⁾	01/31/2030	Common Stock	92,872	$0	207,128	D
Employee stock option (right to buy)	$15.46	10/29/2025		M			27,128	⁽⁴⁾	01/31/2030	Common Stock	27,128	$0	180,000	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR